JOHNSON & JOHNSON is 52.9x more valuable than BIOMARIN PHARMACEUTICAL INC by market capitalization ($574.10 B vs $10.86 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BMRN | JNJ |
|---|---|---|
| Market cap | $10.86 B | $574.10 B |
| US-listed rank | #899 | #20 |
| Revenue (latest FY) | $3.22B | $94.19B |
| Net income (latest FY) | $348.90M | $26.80B |
| Net margin | 10.8% | 28.5% |
| P/E (trailing FY) | 31.1 | 21.4 |
| SEC filings | 2,709 | 984 |
JOHNSON & JOHNSON is 52.9x more valuable than BIOMARIN PHARMACEUTICAL INC by market capitalization ($574.10 B vs $10.86 B).
In their latest fiscal years, BIOMARIN PHARMACEUTICAL INC reported $3.22B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: BIOMARIN PHARMACEUTICAL INC and JOHNSON & JOHNSON, or browse the full rankings.